Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988452 | 0.85 | MEN1 (0.51) | PKMMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL4982608 | 0.85 | SMN1; SMN2 (0.55) | PKMMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL4980965 | 0.83 | SMN1; SMN2 (0.49) | TSHRLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4993378 | 0.82 | KMT2A (0.49) | HSD11B1PKMLMNAMEN1KMT2A | |
| SCHEMBL4983025 | 0.82 | MEN1 (0.53) | TSHRHSD11B1PKMLMNAMEN1 | |
| SCHEMBL4988330 | 0.82 | CD4 (0.50) | HSD11B1PKMHTTGAA | |
| SCHEMBL4988645 | 0.82 | MAPT (0.42) | TSHRPKMLMNAMEN1KMT2A | |
| SCHEMBL4987016 | 0.81 | PKM (0.51) | TSHRHSD11B1PKMLMNASMN1; SMN2 | |
| SCHEMBL4986986 | 0.81 | PKM (0.54) | PKMLMNAMEN1KMT2APKLR | |
| SCHEMBL4992079 | 0.81 | CYP3A4 (0.58) | TSHRHSD11B1PKMLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | MCOLN3 961/4885TSHR 3850/4885HSD11B1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.